Awinsa Life Sciences

Planning for a paradigm shift in the delivery of PV services, AWINSA provides end-to-end services including in its ambit both clinical trial and post-marketing.

[Awinsa Life Sciences @AWINSALS]

Paediatric GI trials face unique safety challenges. Caregiver reported outcomes, developmental variability and signal detection need specialized expertise. AWINSA delivered integrated safety framework ensuring data integrity, compliance & patient safety. https://t.co/Qe32zBS8Hf

[Awinsa Life Sciences @AWINSALS]

Drug safety monitoring is evolving. Real‑world data enables proactive, evidence‑driven pharmacovigilance beyond signal detection.
At AWINSA, we support pharma, biotech & MedTech with end‑to‑end safety solutions, from PV & clinical safety to RWE‑based risk management.
#AWINSA

[Awinsa Life Sciences @AWINSALS]

Over 300M people live with rare diseases, yet orphan drugs often rely on limited safety data. Every patient matters, every case counts. At AWINSA, we supports rare disease products with PV, clinical safety, signal detection, risk management & regulatory writing.

#AWINSA #PV

[Awinsa Life Sciences @AWINSALS]

Pediatric medicines demand unique safety oversight. Children’s evolving physiology can alter drug response, with risks surfacing months or years later. At AWINSA, we supports pharma & biotech with pediatric PV, signal detection, risk management, and end‑to‑end safety operations.

[Awinsa Life Sciences @AWINSALS]

Cancer therapies are evolving fast, and so are safety challenges. From immune related events to REMS and risk plans, oncology PV needs deep lifecycle expertise.

At AWINSA, we deliver PV, safety monitoring, reporting, risk management & regulatory writing.

#AWINSA #Oncology #PV

[Awinsa Life Sciences @AWINSALS]

Vaccine safety demands a structured, scientific approach especially at population scale.
At AWINSA Life Sciences, we supports sponsors with AESI planning, AEFI surveillance, medical review, signal management, risk plans, reporting & global submissions.

[Awinsa Life Sciences @AWINSALS]

A productive experience at #ASCO2026 in Chicago🙂. Great to connect with leaders, researchers & innovators shaping the future of oncology and patient care. At AWINSA Life Sciences, we remain committed to advancing safety, science & collaboration worldwide.

[Awinsa Life Sciences @AWINSALS]

EU MDR demands continuous device safety oversight via PMS, PMCF, PSUR & Vigilance.
At AWINSA, we support MedTech firms with structured PMS programs, vigilance reporting, PSUR prep, EUDAMED submissions & end‑to‑end safety compliance.
#EUMDR #MedicalDevices #PostMarketSurveillance

[Awinsa Life Sciences @AWINSALS]

Biosimilars expand access to advanced therapies while lowering costs—but their complexity demands vigilant pharmacovigilance. AWINSA supports sponsors with global safety oversight, risk management, and regulatory compliance. Register here:https://t.co/TTUIjjkGt3

[Awinsa Life Sciences @AWINSALS]

41st Virtue Insight Pharmacovigilance USA 2026 Conference in Boston, where Dr Sanjeev Miglani, MD Founder and Director of AWINSA Life Sciences, presented on:
"Strategic Risk Management in Pharmacovigilance: Driving Patient Safety Through RMP and REMS"

[Awinsa Life Sciences @AWINSALS]

An insightful session at the 41st Virtue Insight Pharmacovigilance USA 2026 Conference, where Dr. Mugdha Chopra Founder and Director, AWINSA Life Sciences

[Awinsa Life Sciences @AWINSALS]

Day 1 at the 41st Virtue Insight Pharmacovigilance USA 2026 in Boston was a success 😊. Great to connect with industry leaders, pharma & biotech professionals, and dive into evolving PV & clinical safety discussions.

[Awinsa Life Sciences @AWINSALS]

All set for the 41st Virtue Insight Pharmacovigilance USA 2026 in Boston🙂. Excited to connect with industry leaders and showcase how AWINSA supports pharma & biotech with global PV, clinical safety, medical monitoring, affairs, and writing.

[Awinsa Life Sciences @AWINSALS]

Biosimilars expand access to advanced therapies while lowering costs—but their complexity demands vigilant pharmacovigilance. AWINSA supports sponsors with global safety oversight, risk management, and regulatory compliance. Register here:https://t.co/TTUIjjkGt3

[Awinsa Life Sciences @AWINSALS]

Meet our Leadership Team at ASCO Annual Meeting 2026, 29 May - 2 June 2026 at McCormick Place in Chicago, Illinois-USA, to learn more about our Pharmacovigilance, Clinical Safety, Medical Writing, and Medical Information services.
#AWINSA #pharmacovigilance #ASCO2026

[Awinsa Life Sciences @AWINSALS]

Meet our Leadership Team at Pharmacovigilance USA 2026, Virtue Insight Conference Boston, 27 – 28 May 2026 at booth #3, Wyndham Boston Beacon Hill, Boston, USA, to learn more about our Pharmacovigilance, Clinical Safety, Medical Writing, and Medical Information services.

[Awinsa Life Sciences @AWINSALS]

Join us at Wyndham Boston Beacon Hill on 27–28 May 2026 and gain valuable insights from Dr Sanjeev Miglani, MD’s session on “Strategic Risk Management in Pharmacovigilance: Driving Patient Safety Through RMP and REMS” taking place on 28 May at 1:20 PM EST.
#AWINSA

[Awinsa Life Sciences @AWINSALS]

Meet our Leadership Team at ASCO Annual Meeting 2026, 29 May - 2 June 2026 at Hilton Chicago, USA, to learn more about our Pharmacovigilance, Clinical Safety, Medical Writing, and Medical Information services.
#AWINSA #pharmacovigilance #patientsafety #ASCO2026 #DrugDiscovery

[Awinsa Life Sciences @AWINSALS]

Join us at Wyndham Boston Beacon Hill on 27–28 May 2026 and gain valuable insights from Dr. Mugdha Chopra’s session on “Ensuring Compliance in DSUR Processes: Addressing Global Regulatory Complexities” taking place on 28 May at 1:30 PM EST.

[Awinsa Life Sciences @AWINSALS]

On World IBD Day 2026, we raise awareness of the challenges faced by those living with IBD and stress the need for early diagnosis, proper care & continuous support.
At AWINSA, we’re committed to innovation, patient safety & compassionate care.